HR Execs on the Move

FluroTech

www.flurotech.com

 
FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech`s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples derived from cannabis plants. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.flurotech.com
  • 7 – 3535 Research Road NW
    Calgary, AB CAN T2L 2K8
  • Phone: 833.949.8378

Executives

Name Title Contact Details

Similar Companies

Molecular Insight Pharmaceuticals

Molecular Insight Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terumo Interventional Systems

Terumo Interventional Systems is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenVault Corporation

GenVault Corporation is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.